Exhaled nitric oxide in cystic fibrosis: Relationships with airway and lung vascular impairments

European Respiratory Journal

Volumn 34, Issue 1, 2009, Pages 117-124

  Hubert, D ^b   Aubourg, F ^b   Fauroux, B ^c   Trinquart, L ^c,d,e   Sermet, I ^e   Lenoir, G ^d,e   Clement A ^c   Dinh Xuan, A T ^b,d   Louis, B ^f   Mahut, B ^a   Delclaux, C ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b Centre de Ressources et de Compétences Pour la Mucoviscidose ^*  (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f FACULTÉ DE MÉDECINE   (France)

Author keywords

Capillary blood volume; Cystic fibrosis; Exercise test; Exhaled nitric oxide

Indexed keywords

CARBON DIOXIDE; CARBON MONOXIDE; NITRIC OXIDE; OXYGEN;

ADOLESCENT; ADULT; AIRFLOW; AIRWAY; ARTERIAL CARBON DIOXIDE TENSION; ARTERIAL GAS; ARTERIAL OXYGEN SATURATION; ARTERIAL OXYGEN TENSION; ARTICLE; CLINICAL ARTICLE; CYSTIC FIBROSIS; EXERCISE; EXHALATION; FEMALE; HUMAN; LUNG BLOOD VESSEL; LUNG BLOOD VOLUME; LUNG DEAD SPACE; LUNG FUNCTION TEST; MALE; MEMBRANE CONDUCTANCE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY VASCULAR DISEASE; SPIROMETRY; TIDAL VOLUME;

ADOLESCENT; ADULT; BODY MASS INDEX; CARBON MONOXIDE; CHILD; CYSTIC FIBROSIS; EXERCISE TEST; EXHALATION; FEMALE; HUMANS; LUNG; MALE; MUTATION; NITRIC OXIDE; SPIROMETRY;

EID: 69249153008     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00164508     Document Type: Article

References (32)

1. Corey M. Power considerations for studies of lung function in cystic fibrosis. Proc Am Thorac Soc 2007; 4: 334-337.
2. Ricciardolo FL, Sterk PJ, Gaston B, et al. Nitric oxide in health and disease of the respiratory system. Physiol Rev 2004; 84: 731-765.
3. Franklin PJ, Hall GL, Moeller A, et al. Exhaled nitric oxide is not reduced in infants with cystic fibrosis. Eur Respir J 2006; 27: 350-353.
4. Ho LP, Wood FT, Robson A, et al. The current single exhalation method of measuring exhales nitric oxide is affected by airway calibre. Eur Respir J 2000; 15: 1009-1013.
5. Keen C, Olin AC, Edentoft A, et al. Airway nitric oxide in patients with cystic fibrosis is associated with pancreatic function, Pseudomonas infection, and polyunsaturated fatty acids. Chest 2007; 131: 1857-1864.
6. Shin HW, Rose-Gottron CM, Sufi RS, et al. Flow-independent nitric oxide exchange parameters in cystic fibrosis. Am J Respir Crit Care Med 2002; 165: 349-357.
7. Suri R, Paraskakis E, Bush A. Alveolar, but not bronchial nitric oxide production is elevated in cystic fibrosis. Pediatr Pulmonol 2007; 42: 1215-1221.
8. Kelley TJ, Drumm ML. Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells. J Clin Invest 1998; 102: 1200-1207.
9. Texereau J, Fajac I, Hubert D, et al. Reduced exhaled NO is related to impaired nasal potential difference in patients with cystic fibrosis. Vascul Pharmacol 2005; 43: 385-389.
10. Delclaux C, Mahut B, Zerah-Lancner F, et al. Increased nitric oxide output from alveolar origin during liver cirrhosis versus bronchial source during asthma. Am J Respir Crit Care Med 2002; 165: 332-337.
11. Maurey C, Henno P, Delclaux C, et al. Role of endothelin-1 in endothelial dysfunction in cystic fibrosis. Eur Respir J 2007; 30: Suppl. 51, 30s.
12. Ide H, Nakano H, Ogasa T, et al. Regulation of pulmonary circulation by alveolar oxygen tension via airway nitric oxide. J Appl Physiol 1999; 87: 1629-1636.
13. Mahut B, Louis B, Zerah-Lancner F, et al. Validity criteria and comparison of analytical methods of flow-independent exhaled NO parameters. Respir Physiol Neurobiol 2006; 153: 148-156.
14. American Thoracic Society, European Respiratory Society. ATS/ ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005; 171: 912-930.
15. Perillo IB, Hyde RW, Olszowka AJ, et al. Chemiluminescent measurements of nitric oxide pulmonary diffusing capacity and alveolar production in humans. J Appl Physiol 2001; 91: 1931-1940.
16. Macintyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005; 26: 720-735.
17. Roughton F, Forster R. Relative importance of diffusion and chemical reaction rates in determining rate of the exchange of gases in human lung, with special reference to true diffusing capacity of pulmonary membrane and volume of blood in the lung capillaries. J Appl Physiol 1957; 11: 290-302.
18. Glenet SN, De Bisschop C, Vargas F, et al. Deciphering the nitric oxide to carbon monoxide lung transfer ratio: physiological implications. J Physiol 2007; 582: 767-775.
19. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948-968.
20. Wasserman K, Van Kessel AL, Burton GG. Interaction of physiological mechanisms during exercise. J Appl Physiol 1967; 22: 71-85.
21. Wasserman K, Hansen JE, Sue DY, et al. Normal values. In: Wilkins LW, ed. Principles of exercise testing and interpretation. Including pathophysiology and clinical applications. 4th Edn. Philadelphia, Lippincott Williams & Wilkins, 2005; pp. 160-182.
22. George SC, Hogman M, Permutt S, et al. Modeling pulmonary nitric oxide exchange. J Appl Physiol 2004; 96: 831-839.
23. Kerckx Y, Michils A, Van Muylem A. Airway contribution to alveolar nitric oxide in healthy subjects and stable asthma patients. J Appl Physiol 2008; 104: 918-924.
24. Grasemann H, Grasemann C, Kurtz F, et al. Oral L-arginine supplementation in cystic fibrosis patients: a placebo-controlled study. Eur Respir J 2005; 25: 62-68.
25. Girgis RE, Champion HC, Diette GB, et al. Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy. Am J Respir Crit Care Med 2005; 172: 352-357.
26. Merkus PJ, Govaere ES, Hop WH, et al. Preserved diffusion capacity in children with cystic fibrosis. Pediatr Pulmonol 2004; 37: 56-60.
27. Dressel H, Filser L, Fischer R, et al. Lung diffusing capacity for nitric oxide and carbon monoxide: dependence on breath-hold time. Chest 2008; 133: 1149-1154.
28. Moorcroft AJ, Dodd ME, Morris J, et al. Symptoms, lactate and exercise limitation at peak cycle ergometry in adults with cystic fibrosis. Eur Respir J 2005; 25: 1050-1056.
29. Fauroux B, Hart N, Belfar S, et al. Burkholderia cepacia is associated with pulmonary hypertension and increased mortality among cystic fibrosis patients. J Clin Microbiol 2004; 42: 5537-5541.
30. Robert R, Savineau JP, Norez C, et al. Expression and function of cystic fibrosis transmembrane conductance regulator in rat intrapulmonary arteries. Eur Respir J 2007; 30: 857-864.
31. Ionescu AA, Payne N, Obieta-Fresnedo I, et al. Subclinical right ventricular dysfunction in cystic fibrosis. A study using tissue Doppler echocardiography. Am J Respir Crit Care Med 2001; 163: 1212-1218.
32. Linnane SJ, Thin AG, Keatings VM, et al. Glucocorticoid treatment reduces exhaled nitric oxide in cystic fibrosis patients. Eur Respir J 2001; 17: 1267-1270.